Next Article in Journal
IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis
Previous Article in Journal
Ethanol-Induced Mitochondrial Damage in Sertoli Cells is Associated with Parkin Overexpression and Activation of Mitophagy
Previous Article in Special Issue
Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation
Open AccessEditorial

Emerging Cellular Therapies: T Cells and Beyond

1
Department of Applied Sciences, Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
2
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
3
Department of Haematological Medicine, King’s College London, London SE5 9NU, UK
4
Newcastle Biomedicine Cellular Therapies Facility, International Centre for Life, Newcastle University, Newcastle upon Tyne NE1 3BZ, UK
5
Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK
*
Author to whom correspondence should be addressed.
Cells 2019, 8(3), 284; https://doi.org/10.3390/cells8030284
Received: 19 March 2019 / Accepted: 23 March 2019 / Published: 26 March 2019
(This article belongs to the Special Issue Emerging Cellular Therapies: T Cells and Beyond)
Cellular therapies, including those based on T cells, are becoming approved options for clinicians treating a range of diseases. Cytotoxic T lymphocytes (CTLs) can be modified ex vivo to express receptors such as chimeric antigen receptors (CARs) or T cell receptors, allowing them to target tumour cells when infused back into patients with particular cancers. CTLs specific for viruses can be purified ex vivo and reinfused into patients transplanted with haematopoietic stem cells to help combat viral reactivation. Regulatory T cells (Tregs) can be expanded ex vivo for infusion into patients with autoimmunity or allergy, or into those at risk of rejecting transplanted cells or tissues, or suffering graft versus host disease. Effector and regulatory T cells can also be generated by infusion of patient-derived dendritic cells (DCs) conditioned in ways to elicit anti-tumour immunity (CTLs) or Tregs. All such therapies are resource-heavy (particularly in process regulation) and so must be initially targeted to patients that have limited treatment options, but also where they have a chance of being effective. View Full-Text
Keywords: T cells; regulatory T cells; cytotoxic T lymphocytes; CARs; adoptive therapy T cells; regulatory T cells; cytotoxic T lymphocytes; CARs; adoptive therapy
MDPI and ACS Style

Todryk, S.; Jozwik, A.; de Havilland, J.; Hester, J. Emerging Cellular Therapies: T Cells and Beyond. Cells 2019, 8, 284.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop